LEONARD JOHN M 4

What Happened

• John M. Leonard, President, CEO and a director of Intellia Therapeutics (NTLA), was granted awards on March 1, 2026 totaling 381,800 shares: 156,400 restricted stock units (RSUs) and 225,400 derivative awards. Each award was granted at $0.00 per share (i.e., compensation grants, not purchases), with no cash exchanged on grant.

Key Details

• Transaction date: March 1, 2026; Form 4 filed March 3, 2026 (timely).
• Award amounts and price: 156,400 RSUs @ $0.00; 225,400 derivative awards @ $0.00. Total granted = 381,800 units.
• Shares owned after transaction: Not specified in the filing.
• Relevant footnotes:
  • F1: The 156,400 award is RSUs — a contingent right to receive one share per RSU upon vesting.
  • F3: The derivative award includes vesting terms (granted Mar 1, 2026): 33% vests Jan 1, 2027; remaining 67% vests in 24 substantially equal monthly installments thereafter.
  • F2: Some holdings are held by the John M. Leonard 2015 Irrevocable Trust (per the filing).
• Filing timeliness: Filed within the Form 4 reporting window (no late filing indicated).

Context

• These are compensation grants (RSUs and a derivative award with a vesting schedule), not open‑market purchases or sales. Grants typically vest over time and do not represent immediate buying or selling of stock.
• For retail investors, such awards indicate compensation alignment with company performance and retention, but they are not a direct market signal of immediate insider buying or selling.